Holen Sie sich die Stockscreener-App
1.70
2.41%
0.04
Handel nachbörslich:
1.75
0.05
+2.94%
Schlusskurs vom Vortag:
$1.66
Offen:
$1.77
24-Stunden-Volumen:
780.95K
Relative Volume:
4.36
Marktkapitalisierung:
$69.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-78.92M
KGV:
-0.8333
EPS:
-2.04
Netto-Cashflow:
$-72.87M
1W Leistung:
-14.57%
1M Leistung:
-44.26%
6M Leistung:
-59.43%
1J Leistung:
-53.55%
1-Tages-Spanne:
$1.65
$1.89
1-Wochen-Bereich:
$1.60
$2.02
52-Wochen-Spanne:
$1.60
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Firmenname
Vigil Neuroscience Inc
Sektor
Branche
Telefon
857-254-4445
Adresse
100 FORGE ROAD, WATERTOWN
Vergleichen Sie VIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
1.70 | 69.50M | 0 | -78.92M | -72.87M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-04 | Eingeleitet | William Blair | Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2022-09-16 | Eingeleitet | Wedbush | Outperform |
| 2022-08-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Eingeleitet | Jefferies | Buy |
| 2022-02-01 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vigil Neuroscience Inc Aktie (VIGL) Neueste Nachrichten
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd Purchases 12,000 Shares - MarketBeat
Vigil Neuroscience director Budd Haeberlein buys $20,520 in shares - Investing.com
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock - Investing.com India
Vigil neuroscience CEO Ivana Magovcevic-Liebisch acquires $8,350 in stock By Investing.com - Investing.com Australia
Vigil Neuroscience stock hits 52-week low at $2.07 - Investing.com India
Vigil Neuroscience stock hits 52-week low at $2.07 By Investing.com - Investing.com South Africa
Vigil Neuroscience (NASDAQ:VIGL) and ProKidney (NASDAQ:PROK) Head-To-Head Contrast - Defense World
Vigil Neuroscience initiated with an Outperform at William Blair - MSN
FY2024 Earnings Estimate for VIGL Issued By William Blair - MarketBeat
FY2024 Earnings Forecast for VIGL Issued By William Blair - Defense World
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - The Eastern Progress Online
William Blair Initiates Coverage on Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Vigil neuroscience CEO Ivana Magovcevic-Liebisch buys $11,700 in stock By Investing.com - Investing.com Australia
Vigil neuroscience CEO Ivana Magovcevic-Liebisch buys $11,700 in stock - Investing.com
William Blair Initiates Coverage of Vigil Neuroscience (VIGL) with Outperform Recommendation - MSN
William Blair initiates Vigil Neuroscience with Outperform By Investing.com - Investing.com Nigeria
William Blair initiates Vigil Neuroscience with Outperform - Investing.com
Vigil Neuroscience shares rated Outperform by William Blair, advancing in Alzheimer's treatment - Investing.com Nigeria
Vigil Neuroscience: Down On A Competitor's Failure (NASDAQ:VIGL) - Seeking Alpha
Contrasting Vigil Neuroscience (NASDAQ:VIGL) and Surrozen (NASDAQ:SRZN) - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
JMP Securities Reiterates Market Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Guggenheim maintains Buy on Vigil Neuroscience stock post-Alector trial By Investing.com - Investing.com Canada
Vigil Neuroscience stock hits 52-week low at $2.45 - Investing.com India
Vigil Neuroscience stock hits 52-week low at $2.45 By Investing.com - Investing.com UK
Guggenheim maintains Buy on Vigil Neuroscience stock post-Alector trial - Investing.com
Vigil Neuroscience's (VIGL) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
Citadel Advisors LLC Adjusts Position in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Deep Track Capital, LP Increases Stake in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience to Present at Upcoming Investor Conferences - GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateOn November 7, 2024, Vigil Neuroscience, Inc. (NASDAQ: VIGL) released its financial results for the third quarter ended September 30, 2024. The company, dedic - Defense World
Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00 - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Given New $24.00 Price Target at Wedbush - MarketBeat
HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience Advances Key Clinical Programs - TipRanks
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake - Yahoo Finance
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference - GlobeNewswire
abrdn plc Makes New $799,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully - Simply Wall St
Vigil Neuroscience retains stock target on TREM2 potential - Investing.com
Vigil Neuroscience retains stock target on TREM2 potential By Investing.com - Investing.com Australia
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors - BioSpace
Quanterix Appoints Ivana Magovčević-Liebisch to Board of Directors - citybiz
Point72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Finanzdaten der Vigil Neuroscience Inc-Aktie (VIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vigil Neuroscience Inc-Aktie (VIGL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):